|Articles|May 9, 2017
WIRB-Copernicus Acquires Again
WIRB-Copernicus Group (WCG) has announced the acquisition of MedAvante and ProPhase, and has named Dr. Jeffrey Litwin as CEO of the combined organization.
Advertisement
WIRB-Copernicus Group (WCG) has announced the acquisition of MedAvante and ProPhase, and has named Dr. Jeffrey Litwin as CEO of the combined organization. This acquisition provides WCG’s clients with a more comprehensive and integrated suite of study start-up solutions.
Read the full release
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
FDA Approves GSK’s Exdensur for Severe Asthma Based on SWIFT Phase III Data
2
ACT Brief: Patient Preferences in Remote Trials, Sanofi’s Neurology and Immunology Deals, and AI-Driven Biomarkers in Oncology
3
Rethinking Operational Models to Reduce Site Burden in 2026
4
What Patients Want from Remote Trials: New Survey Data Reveals Preferences Around Usability, Trust, and Participation
5